J
Jian Hua Shi
Publications - 43
Citations - 2249
Jian Hua Shi is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 5 publications receiving 1625 citations.
Papers
More filters
Journal ArticleDOI
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu,Caicun Zhou,Chengping Hu,Jifeng Feng,Shun Lu,Yunchao Huang,Wei Li,Mei Hou,Jian Hua Shi,Kye Young Lee,Chong-Rui Xu,Dan Massey,MI-Young Kim,Yang Shi,Sarayut Lucien Geater +14 more
TL;DR: Afatinib significantly improves progression-free survival with a tolerable and manageable safety profile in Asian patients with EGFR mutation-positive advanced lung NSCLC and should be considered as a first-line treatment option for this patient population.
Journal ArticleDOI
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.
Zi-Xian Wang,Chengxu Cui,Jun Yao,Yanqiao Zhang,Mengxia Li,Jifeng Feng,Shujun Wang,Yun Fan,Jian Hua Shi,Lizhi Zhang,Lin Shen,Yongqian Shu,Cailian Wang,Tian-yang Dai,Teng Mao,Long Chen,Zengqing Guo,Bo Liu,Hongming Pan,Shundong Cang,Yi Jiang,Junye Wang,Min Ye,Zhendong Chen,Da Jiang,Qin Lin,Wei Ren,Junsheng Wang,Lin Wu,Yong Xu,Zhanhui Miao,Meili Sun,Conghua Xie,Ying Liu,Qifeng Wang,Lina Zhao,Canhong Huang,Ke Jiang,Kunyu Yang,Dao-Rui Li,Yunpeng Liu,Zhitu Zhu,Ri Shu Chen,Liqun Jia,Wei Liu,Wangjun Liao,Hong-Xu Liu,Dai-Yuan Ma,Jie Ma,Yanru Qin,Zhi-xiang Shi,Qichun Wei,Ke Xiao,Yan Zhang,Ying Zhang,Xin Chen,Guanghai Dai,Jianxing He,Junhe Li,Guanghui Li,Yong Li,Zhihua Liu,Xianglin Yuan,Junping Zhang,Zhichao Fu,Yifu He,Fang Ju,Zheng Liu,Peng Tang,Tie-Jun Wang,Weibo Wang,Jing Zhang,Xianming Luo,Xiongwen Tang,Rena J. May,Hui Feng,Sheng Yao,Patricia Keegan,Rui-Hua Xu,Feng Wang +79 more
TL;DR: Toripalimab plus TP significantly improved progression-free survival (PFS) and overall survival (OS) in patients with treatment-naïve, advanced esophageal squamous cell carcinoma (ESCC) with a manageable safety profile as mentioned in this paper .
Journal ArticleDOI
LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung.
Yi-Long Wu,Caicun Zhou,Chengping Hu,Ji Feng Feng,Shun Lu,Yunchao Huang,Wei Li,Mei Hou,Jian Hua Shi,Kye Young Lee,Dan Massey,Yang Shi,Jiongjie Chen,V. Zazulina,Sarayut Lucien Geater +14 more
TL;DR: This study compared the safety and efficacy of first-line A with GC in EGFR M+ Asian pts and found PFS was significantly prolonged with A compared with GC by independent review.
Journal ArticleDOI
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
Qiang Zhou,Ming Chen,Ou Jiang,Yi Pan,Desheng Hu,Qin Lin,Gang Wu,Jiuwei Cui,Jianhua Chang,Yufeng Cheng,Cheng Huang,Anwen Liu,Nong Yang,Youling Gong,Changbao Zhu,Zhiyong Ma,Jian Fang,Gongyan Chen,Jun Zhao,Anhui Shi,Ying Jun Lin,Guanghui Li,Yunpeng Liu,Dong Wang,Rong Wu,Xin-Hua Xu,Jian Hua Shi,Zhihua Liu,Na Cui,Jingru Wang,Qian Wang,Ran Zhang,Jason Yang,Yi-Long Wu +33 more
TL;DR: GEMSTONE-301 as mentioned in this paper is a randomized, double-blind, placebo-controlled, phase 3 trial in patients with stage III non-small-cell lung cancer (NSCLC) whose disease had not progressed after concurrent or sequential chemoradiotherapy.
Journal ArticleDOI
Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer
Sarayut Lucien Geater,Chong-Rui Xu,Caicun Zhou,Chengping Hu,Jifeng Feng,Shun Lu,Yunchao Huang,Wei Li,Mei Hou,Jian Hua Shi,Kye Young Lee,Mike K. Palmer,Yang Shi,Juliane Lungershausen,Yi-Long Wu +14 more
TL;DR: Afatinib improved PFS and PROs versus chemotherapy in EGFR mutation-positive NSCLC patients and was associated with statistically significant worsening in QoL measured before tumor assessment, underscores the value of PFS as a clinically relevant end point.